▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4208 by analyst upside · 2026-09-27
TXG
10x Genomics, Inc.
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
-34.0%
implied upside to consensus target
Current Price $85.71
Consensus Target $56.6
Bull Target $90.0
Bear Target $40.0
Analysts Covering 15
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
4
Hold
10
Sell
0
52-Week Low $11.16
52-Week High $86.16
YTD Return +415.7%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E 779.2x
EPS (TTM) $-0.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $617M
Profit Margin -12.2%
52-WEEK RANGE
52-Week Low $11.16
52-Week High $86.16
Current Price $85.71
Bear Target $40.0
Bull Target $90.0
● Now $85.71 ● Target $56.6
TRADING DATA
Avg Volume 3.0M
YTD Return +415.7%
Analyst Count 15
Consensus Hold
Upside to Target -34.0%
Last Updated 2026-09-27

ANALYST SUMMARY

10x Genomics, Inc. (TXG) is currently trading at $85.71 with a Wall Street consensus price target of $56.6, which is 34.0% below the current price over the next 12 months. 15 analysts currently cover TXG, with a consensus rating of Hold - 33% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $90.0, while the most cautious has a target of $40.0.

TXG operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 415.7% year-to-date and is currently trading near the upper end of its 52-week range of $11.16 – $86.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CAI -12.0%
Caris Life Sciences, Inc.
$9B · P/E 3.3x · Buy
UHS +8.7%
Universal Health Services, Inc.
$11B · P/E 7.3x · Hold
FMS +11.7%
Fresenius Medical Care AG
$12B · P/E 12.0x · Hold
EXEL -7.7%
Exelixis, Inc.
$14B · P/E 18.3x · Hold
SOLV +4.9%
Solventum Corporation
$15B · P/E 10.9x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for TXG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Neutral → Neutral 2026-09-09 33% win rate (6 calls)
RBC Capital ● Initiated
Sector Perform 2026-09-01 Building track record
Stephens & Co. - Reiterated
Overweight → Overweight 2026-08-12 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-08-10 14% win rate (7 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-10 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-08-07 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-08-07 Building track record
Leerink Partners - Reiterated
Market Perform → Market Perform 2026-07-17 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
21/30
Consensus clarity
18/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →